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Ovarian cancer is the most frequent cause of death from gynaecological cancer in the Western world. Current prognostic factors do
not allow reliable prediction of response to chemotherapy and survival for individual ovarian cancer patients. Epidermal growth factor
receptor (EGFR) and HER-2/neu are frequently expressed in ovarian cancer but their prognostic value remains unclear. In this study,
we investigated the expression and prognostic value of EGFR, EGFR variant III (EGFRvIII), HER-2/neu and important downstream
signalling components in a large series of epithelial ovarian cancer patients. Immunohistochemical staining of EGFR, pEGFR, EGFRvIII,
Her-2/neu, PTEN (phosphatase and tensin homologue deleted on chromosome 10), total and phosphorylated AKT (pAKT) and
phosphorylated ERK (pERK) was performed in 232 primary tumours using the tissue microarray platform and related to
clinicopathological characteristics and survival. In addition, EGFRvIII expression was determined in 45 tumours by RT–PCR. Our
results show that negative PTEN immunostaining was associated with stage I/II disease (P¼0.006), non-serous tumour type
(P¼0.042) and in multivariate analysis with a longer progression-free survival (P¼0.015). Negative PTEN staining also predicted
improved progression-free survival in patients with grade III or undifferentiated serous carcinomas (P¼0.011). Positive pAKT staining
was associated with advanced-stage disease (P¼0.006). Other proteins were expressed only at low levels, and were not associated
with any clinicopathological parameter or survival. None of the tumours were positive for EGFRvIII. In conclusion, our results indicate
that tumours showing negative PTEN staining could represent a subgroup of ovarian carcinomas with a relatively favourable
prognosis.
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Five-year survival of advanced-stage ovarian cancer patients
remains only 15–25%, despite intensive surgical treatment and
combination chemotherapy. Development of intrinsic or acquired
resistance to platinum-containing chemotherapy is the major
obstacle in the treatment of patients with ovarian cancer (Bhoola
and Hoskins, 2006). Current clinicopathological prognostic factors
do not allow individualised prediction of response to chemother-
apy or disease outcome. Identification of molecular biological
prognostic factors would be of great value for more accurately
classification of ovarian carcinomas into subtypes with a different
clinical outcome, thereby possibly also enabling individualised
treatment strategies (Crijns et al, 2006a).
Epidermal growth factor receptor (EGFR) and HER-2/neu are
members of the erbB family of tyrosine kinase receptors. Aberrant
activity of EGFR and HER-2/neu has been shown to be important
in tumour growth and development. Binding of ligand to the
ectodomain of ErbB receptors results in receptor autophosphor-
ylation and initiation of downstream signalling cascades, such as
the PI3K/AKT pathway and the Ras/Raf/MEK/Erk pathway.
Activation of these pathways in cancer has been associated with
increased angiogenesis, metastasis, dedifferentiation, growth and
protection from apoptosis (Yarden and Sliwkowski, 2001).
Phosphatase and tensin homologue deleted on chromosome 10
(PTEN) directly antagonises the PI3K/AKT pathway by preventing
the phosphorylation of AKT (Sansal and Sellers, 2004).
Several studies have shown that overexpression of HER-2/neu
and EGFR, as well as alterations in their downstream targets AKT
and extracellular signal-regulated kinase (ERK) is associated with
resistance to platinum- and taxane-based chemotherapy. Treat-
ment with agents directed against these proteins may enhance
chemotherapy-induced cell death (Ciardiello et al, 2000; Altomare
et al, 2004; Qiu et al, 2005; Lee et al, 2005b) The prognostic
significance of EGFR and HER-2/neu has been extensively studied Revised 7 April 2008; accepted 22 May 2008
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sin ovarian cancer, but remains unclear. A recent meta-analysis
revealed that abnormal expression of these markers appears to be
associated with poor 5-year survival, but this is not a uniform
finding (Crijns et al, 2003).
The EGFR variant III (EGFRvIII) lacks exons 2–7 of
the extracellular domain of the receptor. Although EGFRvIII
is unable to bind ligand, it is constitutively phosphorylated and
able to activate downstream signalling pathways (Pedersen et al,
2001). EGFRvIII expression is thought to confer resistance to
cisplatin and paclitaxel (Nagane et al, 1998; Montgomery et al,
2000). The two studies investigating EGFRvIII expression in
ovarian cancer show conflicting results (Moscatello et al, 1995;
Lassus et al, 2006).
The aim of the present study was to investigate the prognostic
significance of EGFR and HER-2/neu, and their downstream
targets AKT, ERK and PTEN in a large series of 232 epithelial
ovarian cancer patients using the tissue microarray (TMA)
platform. In addition to immunostaining, we determined the
expression of EGFRvIII in more detail in a subset of 45 ovarian
tumours using the more sensitive method RT–PCR.
MATERIALS AND METHODS
Patients
Since 1985 all clinicopathological and follow-up data of 329
epithelial ovarian cancer patients treated at the University Medical
Centre Groningen have been prospectively stored in a database. All
patients gave informed consent for data storage and tumour
collection, and studies were conducted in accordance with the
Declaration of Helsinki principles and institutional review board
policies. For the current study all consecutive chemonaive ovarian
cancer patients for whom sufficient paraffin-embedded tumour
tissue and complete follow-up data were available were selected
(n¼232).
Patients were surgically staged according to FIGO (International
Federation of Gynaecology and Obstetrics) criteria (Cancer
Committee of the International Federation of Gynaecology and
Obstetrics, 1986). Optimal and suboptimal debulking was defined
as the largest residual tumour lesions having a diameter of o2cm
orX2cm. The histology of all carcinomas was determined by a
gynaecological pathologist according to WHO (World Health
Organization) criteria (Scully, 2004).
Response to chemotherapy was evaluated according to WHO
criteria (World Health Organization, 1979). When indicated,
intervention surgery was performed after three cycles of chemo-
therapy, while until 1996 second-look surgery was regularly
performed after six cycles of chemotherapy.
TMA construction and immunostaining
Tissue microarrays were constructed as described previously (de
Graeff et al, 2006). In total, four tissue cores from 232 primary
tumours and 45 paired tumours obtained at second-look surgery
or surgery for recurrent disease were included on eight TMAs.
Antigen retrieval methods, primary antibodies and detection
techniques are provided as supplementary data. Sections (4mm)
were de-paraffinised in xylene and endogenous peroxidase was
blocked by incubation in 0.3% hydrogen peroxide for 30min. After
antigen retrieval, slides were incubated in normal goat serum
(HER-2/neu), horse serum (EGFR, pEGFR), bovine serum
(phosphorylated AKT (pAKT), phosphorylated ERK (pERK),
PTEN, total AKT) or blocking solution (Dako, Cambridgeshire,
UK) for EGFR. For pEGFR, pAKT, pERK and PTEN staining,
endogenous avidin and biotin activity was blocked using a
blocking kit (Vector Laboratories, Burlingame, UK). HER-2/neu
staining was performed in a Dako autostainer (Dako). Staining
was visualised by 303-diaminobenzidine tetrahydrochloride and
sections were counterstained with haematoxylin. EGFRvIII stain-
ing was kindly performed by Dr A Jungbluth, Ludwig Institute for
Cancer Research, New York, USA.
Positive controls included separate TMA slides containing
multiple tumour and normal tissues for EGFR and pEGFR,
sections from tumours with known marker expression for HER-
2/neu and PTEN, ovarian cancer cell line A2780 for AKT, pAKT
and ERK, and glioblastoma cell line U87 transfected with an
EGFRvIII plasmid for EGFRvIII staining (Jungbluth et al, 2003).
Negative controls were obtained by omission of the primary
antibody, and by incubation with normal rabbit IgG for total AKT.
All control experiments gave satisfactory results. Antigen pre-
servation was verified by vimentin staining, which was positive in
all tumour and control samples.
Evaluation of immunostaining was independently performed by
two observers (KAH and PDG), blinded to clinical data. The
agreement between the two observers was490%. Discordant cases
were reviewed with a gynaecological pathologist and were
re-assigned on consensus of opinion.
HER-2/neu staining was scored according to the HercepTest
protocol (Lebeau et al, 2001), and was considered positive
when410% of tumour cells showed moderate or strong membrane
staining. For EGFR and EGFRvIII, tumours demonstrating410%
membrane staining were considered to show overexpression (Elie
et al, 2004; Skirnisdottir et al, 2004; Cunningham et al, 2005).
Overexpression of p-EGFR was defined as 45% membrane or
granular cytoplasmic staining (Han et al, 2004). Tumours were
considered positive for AKT or ERK if 410% of tumour cells
showed positive cytoplasmic and/or nuclear staining (Kurose et al,
2001). Phosphatase and tensin homologue deleted on chromosome
10 staining in tumour sample was scored relative to staining in
vascular endothelium (Gimm et al, 2000; Choe et al, 2003), and was
regarded as negative when staining was completely absent in
tumour tissue but present in vascular endothelium.
RT–PCR for EGFRvIII
We performed RT–PCR analysis on a subset of 45 frozen tumour
samples, of which 35 showed positive immunostaining for
(p)EGFR or downstream targets and 10 were completely negative.
Positive controls included a glioblastoma tumour sample expres-
sing both the wild-type EGFR (wtEGFR) and EGFRvIII, and a cell
line transfected with an EGFRvIII plasmid (Jurkat.EGFRvIII;
Bremer et al, 2005).
Extraction of RNA and cDNA synthesis was performed as
previously described (Crijns et al, 2006b). We performed RT–PCR
separately for EGFRvIII and the housekeeping gene GAPDH.
Primers were 50-GGGCTCTGGAGGAAAAGAAA-30 and 50-AGGCC
CTTCGCACTTCTTAC-30 for amplifying EGFRvIII and wtEGFR (Ji
et al, 2006), and 50-CACCCACTCCTCCACCTTTG-30 and 50-CCAC
CACCCTGTTGCTGTAG-30 for amplifying GAPDH. The protocol
was as follows: initial denaturation at 951C for 10min, followed by
30 (EGFRvIII) or 25 cycles (GAPDH) of amplification (1min at
951C, 1min at 561C for EGFRvIII and at 601C for GAPDH, and 90s
at 721C) and a final extension step at 721C for 7min. The RT–PCR
products (128bp for EGFRvIII, 929bp for wtEGFR and 110bp for
GAPDH) were visualised by 1.5% agarose gel electrophoresis in
1  Tris-Borate EDTA buffer.
Statistical analysis
Statistical analysis was carried out using the SPSS 12.01 software
package. Cut-off points for positive marker expression were
determined a priori. All cases with o2 evaluable cores were
excluded from analysis.
Comparisons between paired tumour samples obtained before
and after chemotherapy were made using the Wilcoxon rank sum
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stest. Associations between markers, and between markers and
clinicopathological characteristics were performed using the w
2 or
Fisher’s exact test, where appropriate.
The end points investigated were progression-free and disease-
specific overall survival (PFS and OS), defined as the time from
primary surgery until progression/relapse of the disease or death
of ovarian cancer, respectively. Response to platinum-based
chemotherapy could only be evaluated in patients who had
measurable disease after primary surgery and/or during first-line
chemotherapy (n¼130), and was defined according to WHO
criteria (World Health Organization, 1979).
For univariate and multivariate survival analysis Cox propor-
tional hazards model was used. Categorised covariates that were
significant in univariate analysis were entered simultaneously into
the multivariate model. Response to chemotherapy was analysed
using logistic regression analysis. For this analysis, response was
entered as a categorical variable (complete and partial response vs
stable and progressive disease). P-values o0.05 were considered
statistically significant.
RESULTS
Patients
A total of 232 patients (median age 57.8 years, range 22–90)
treated at the Groningen University Medical Centre between 1985
and 2002 were selected for the present study (Table 1). Of them 64
(27.6%) patients presented with stage I/II disease and 166 (71.5%)
patients with stage III/IV disease. Optimal debulking was achieved
in 61 (96.8%) stage I/II patients and 48 (31.0%) stage III/IV
patients. First-line chemotherapy regimens were platinum based in
100 (43.1%) patients and platinum- and taxane-based in 72
(31.0%) patients. Total 25 (10.8%) patients were treated with other
regimens, and 32 (13.8%) patients did not receive chemotherapy
because of stage Ia disease, comorbidity or treatment refusal.
For stage I/II patient, 5-year PFS was 73.0% (median 53 months,
range 0–207) and 5-year OS was 78.9% (median 58 months, range
0–207). For stage III/IV patients, 5-year PFS was 13.8% (median
13.8 months, range 0–149) and 5-year OS was 22.3% (median 21
months, range 0–213). Five-year survival for the whole cohort was
39.2%.
Immunostaining and RT–PCR
The number of non-evaluable primary tumours due to core loss
during staining procedures or absence of tumour tissue ranged
from 2 (0.9%) for HER-2/neu staining to 10 (4.3%) for pERK
staining. Positive staining was present in 6.2% of tumours for
EGFR, 5.1% of tumours for HER-2/neu, 11.8% tumours for pEGFR,
100% of tumours for total AKT, 8.3% of tumours for pAKT and
36.9% of tumours for pERK (Table 2; Figure 1). Of 224 tumours, 69
(30.8%) showed completely negative PTEN staining. None of the
tumour samples stained positive for EGFRvIII, nor could EGFRvIII
be detected by RT–PCR. Staining for pERK was more frequent in
tumour samples obtained after three or six cycles of chemotherapy
compared to paired primary tumour samples (65 vs 37%,
P¼0.020). For all other proteins, staining patterns in primary
tumours were comparable to paired residual or recurrent tumour
samples (Table 2).
Unexpectedly, PTEN staining was positively correlated with
pAKT staining (P¼0.034). No associations were found between
other proteins (data not shown).
Clinicopathological characteristics
Overexpression of EGFR was more frequent in non-serous
tumours (P¼0.017; Table 3). Stage III/IV tumours more often
showed overexpression of pAKT (P¼0.029). Loss of PTEN was
related to stage I/II disease (P¼0.006). Furthermore, negative
PTEN immunostaining was associated with non-serous tumour
type (P¼0.042), occurring in 25% of serous, 39% of endometrioid,
42% of mucinous and 56% of clear cell tumours. No other
associations between protein expression and clinicopathological
variables were found.
Response to chemotherapy and survival
Univariate Cox regression analysis revealed that patients with a
PTEN-negative tumour had a better PFS and OS (Table 4; Po0.001
and P¼0.037, respectively). On the basis of recent publications
dividing ovarian carcinomas into subgroups with specific mole-
cular alterations (Bell, 2005; Press et al, 2008), we performed
subgroup analyses for early and late stage patients, and for patients
with grade III and undifferentiated carcinomas. Subgroup analysis
for stage I/II and stage III/IV patients showed that PTEN predicts
PFS only in the early stage group (HR 0.29, 95% CI 0.095–0.9,
P¼0.032 for stage I/II patients, HR 0.74, 95% CI 0.48–1.15,
P¼0.18 for stage III/IV patients). Loss of PTEN also predicted
improved PFS in 91 poorly differentiated serous carcinomas, of
which 20 (22.0%) were PTEN negative (HR 0.43, 95% CI 0.23–0.83,
P¼0.011).
In multivariate analysis PTEN staining (P¼0.015), FIGO stage
(P¼0.013) and residual tumour after primary surgery (Po0.001)
independently predicted PFS (Table 5). Tumour stage (P¼0.023)
and residual tumour (Po0.001), but not PTEN staining (P¼0.833)
were significant prognostic factors in multivariate analysis for OS.
Table 1 Clinicopathological characteristics
All patients (n¼232)
N %
FIGO stage
Stage I 45 19.4
Stage II 19 8.2
Stage III 133 57.3
Stage IV 33 14.2
Missing 2 0.9
Tumour type
Serous 129 55.6
Mucinous 27 11.6
Clear cell 17 7.3
Endometrioid 33 14.2
Adenocarcinoma NOS 9 3.9
Other 17 7.3
Tumour grade
Grade I 39 16.8
Grade II 51 22.0
Grade III 104 44.8
Undifferentiated 14 6.0
Missing 24 10.3
Residual disease
o2cm 111 47.8
X2cm 109 47.0
Missing 12 5.2
Type of chemotherapy
No chemotherapy 32 13.8
Platinum based 100 43.1
Platinum/taxane based 72 31.0
Other regimen 25 10.8
Missing 3 1.3
FIGO¼ International Federation of Gynaecology and Obstetrics; NOS¼not
otherwise specified.
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sOther markers were not associated with survival. Protein expres-
sion did not predict response to platinum-based chemotherapy.
DISCUSSION
Our study in a large, well-defined series of epithelial ovarian
cancer patients shows that PTEN-negative tumours might
represent a subgroup of ovarian carcinomas with a relatively
favourable prognosis. To our knowledge this is the first study
describing a relationship between negative PTEN staining and
improved survival in ovarian cancer. Although a relationship
between negative PTEN staining and improved survival has been
described for endometrial cancer patients (Risinger et al, 1998),
previous studies in ovarian cancer found no or an inverse
relationship between PTEN and prognosis (Schondorf et al, 2003;
Wang et al, 2005; Lee et al, 2005a). These contrasting results could
be explained by the fact that previous studies either did not have
the power to evaluate possible relations with survival, or restricted
their analysis to stage III/IV ovarian cancer patients. In the current
study PTEN staining was of prognostic significance mainly in the
stage I/II group and in poorly differentiated serous carcinomas.
We found negative PTEN expression in 30.8% of tumours, which
is in agreement with previous studies (Wang et al, 2005; Lee et al,
2005a; Hashiguchi et al, 2006). In ovarian cancer, loss-of-
heterozygosity (LOH) at the PTEN locus (10q23.3) occurs in 31–
45% of tumours, whereas mutations of the second PTEN allele are
relatively rare (Maxwell et al, 1998; Obata et al, 1998; Kurose et al,
2001). Loss of protein expression is therefore also thought to arise
through other mechanisms, such as DNA methylation (Sansal and
Sellers, 2004).
Interestingly, we showed a high rate of negative PTEN staining
in endometrioid and clear cell tumours. A high rate of PTEN loss
in clear cell and endometrioid carcinomas has also been shown in
previous, much smaller studies (Obata et al, 1998; Hashiguchi et al,
2006). Both cancers are thought to at least partly arise from
endometriosis. Sato et al (2000) showed that in three out of five
ovarian carcinomas associated with endometriosis, LOH at 10q23.3
occurs in both the carcinoma and in endometriotic lesions,
implicating that LOH is an early event in carcinogenesis and that
PTEN is involved in the progression from endometriotic precursor
lesion to clear cell or endometrioid ovarian cancer.
Our results show that negative PTEN staining is strongly
associated with early stage disease and a non-serous tumour type.
Recent studies suggest that ovarian carcinomas could be divided in
two categories. The first category, called type I, includes low-grade
serous, mucinous, clear cell and endometrioid tumour with
frequent alterations in BRAF, KRAS and PTEN. Type I tumours
are thought to arise from precursor lesions such as endometriosis
and have a relatively good prognosis. In contrast, type II tumours,
including high-grade serous and undifferentiated carcinomas
characterised by p53 mutations and overexpression/amplification
of HER-2/neu and AKT2, tend to show a highly aggressive
behaviour (Shih and Kurman, 2004; Bell, 2005). In the present
study, we identified a relationship of pAKT expression with late
stage disease. Moreover, our previous work showed that over-
expression of p53 mostly occurs in high-grade, late stage, serous
carcinomas (de Graeff et al, 2006). Our combined results therefore
support this model of ovarian carcinogenesis.
A recent study by Press et al (2008) suggests that type II ovarian
tumours can be subclassified into three groups based on their
BRCA1 status. Their results indicate that poorly differentiated
serous carcinomas with BRCA1 mutations frequently show loss of
PTEN. The molecular mechanism underlying the relationship
between loss of PTEN and BRCA1 mutations in ovarian cancer
remains unknown. Possibly, ineffective DNA repair in BRCA1-
linked tumours results in specific mutations of the PTEN gene
(Foulkes, 2008; Saal et al, 2008). On the basis of these observations
we performed survival analysis in a subgroup of 91 poorly
differentiated serous carcinomas. We were able to show that loss of
PTEN was indeed associated with improved PFS in this subgroup
of ovarian carcinomas. Patients with BRCA1-linked hereditary
tumours have a favourable survival compared to sporadic
tumours, possibly because of a good response to chemotherapy
(Boyd et al, 2000; Chetrit et al, 2008). The link between PTEN and
BRCA1 status might therefore explain an improved disease
outcome in a subgroup of patients with an otherwise very poor
prognosis. In that case, IHC staining of PTEN may be a rapid way
of identifying tumours most likely to carry BRCA1 mutations.
Subsequently, those patients might benefit from treatments with
agents selectively targeting BRCA mutant tumour cells, such as
poly(ADP-ribose) polymerase 1 inhibitors (Farmer et al, 2005).
In the current study, loss of PTEN was associated with improved
PFS, but not OS. As PFS is closely related to response to
chemotherapy, these results might indicate that patients with
PTEN negative tumours respond favourably to first-line therapy.
In the current study we did not observe a relationship between
PTEN status and response to chemotherapy. However, this analysis
was limited to patients who had measurable disease before start
of chemotherapy or measurable disease progression during
Table 2 Results of immunostaining
EGFR pEGFR HER-2/neu pAKT pERK PTEN
Primary tumours (n¼232)
Evaluable
a 228 228 230 228 222 224
Positive 16 (7.0%) 27 (11.8%) 12 (5.2%) 19 (8.3%) 82 (36.9%) 155 (69.2%)
Negative 212 (93.0%) 201 (88.2%) 218 (94.8%) 209 (91.7%) 140 (63.1%) 69 (30.8%)
Second look (n¼26)
Evaluable
a 22 22 22 21 20 19
Positive 4 (18.2%) 5 (22.7%) 1 (4.5%) 4 (19.0%) 13 (65.0%) 16 (84.2%)
Negative 18 (81.8%) 17 (77.3%) 21 (95.5%) 17 (81.0%) 7 (35.0%) 3 (15.8%)
P-value
b 0.317 0.317 1.000 0.317 0.020 0.655
Recurrent disease (n¼19)
Evaluable
a 19 19 18 18 19 18
Positive 2 (10.5%) 3 (15.8%) 2 (11.1%) 3 (16.7%) 8 (42.1%) 17 (94.4%)
Negative 17 (89.5%) 16 (84.2%) 16 (88.9%) 15 (83.3%) 11 (57.9%) 1 (5.6%)
P-value
c 0.317 0.564 0.157 0.317 0.317 0.317
Bold signifies Po0.05.
aNumber of evaluable cases (cases with o2 evaluable cores were excluded from the analysis).
bP-value from Wilcoxon rank sum test for comparison of
protein expression between tumour samples from primary surgery and from second look.
cP-value from Wilcoxon rank sum test for comparison of protein expression between
tumour samples from primary surgery and surgery for recurrent disease.
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streatment. Response to chemotherapy could therefore only be
analysed in a subset of advanced-stage patients with a very poor
prognosis. One possible explanation for the lack of association
between negative PTEN staining and OS might be explained by the
fact that tumours can acquire secondary mutations during or after
platinum-based chemotherapy (Sakai et al, 2008). Once a patient
presents with progressive or recurrent disease, these mutations
may render the tumour insensitive to platinum-based chemo-
therapy irrespective of the PTEN status.
We did not observe any association between EGFR and HER-2/
neu immunostaining and disease outcome, confirming results of a
previous study also from our institution (Van Der Zee et al, 1995).
Previous studies on the relationship between EGFR or HER-2/neu
overexpression and clinicopathological characteristics, response to
chemotherapy and survival have shown conflicting results
(Camilleri-Broet et al, 2004; Elie et al, 2004; Nielsen et al, 2004;
Psyrri et al, 2005). One of the most important reasons for these
inconclusive data is the considerable methodological variability
among studies (Hall et al, 2004). Techniques used to determine
marker expression, antibodies and scoring systems used for
immunostaining vary widely between studies. For the present
investigation, we aimed to use well-characterised antibodies that
have been extensively studied in other tumour types, and, if
possible, used well-defined scoring criteria that have been shown
to be reproducible. We have sought to adhere to the REMARK
guidelines for publishing prognostic factor studies (McShane et al,
2005). The use of these guidelines and of standardised methods
should aid in increasing transparency and reproducibility of
AB
C D
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F
Figure 1 Results of immunostaining. (A) and (B) show positive immunostaining for epidermal growth factor receptor (EGFR) and pEGFR, respectively, in
the same tumours. Positive immunostaining for pAKT and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) in the same tumour is
shown in (C) and (D), respectively. Figures (E–G) show positive immunostaining for EGFRvIII (positive control, E), HER-2/neu (F), pERK (G) and total
AKT (H).
ErbB signalling pathway in ovarian cancer
P de Graeff et al
345
British Journal of Cancer (2008) 99(2), 341–349 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sprognostic factor studies in ovarian cancer and other tumour
types.
As tumours showing evidence of strong signalling through a
particular pathway are thought to have a high chance of
responding to therapies directed against this pathway, the
identification of reliable biomarkers could aid in selecting patients
who are most likely to benefit from targeted therapy (Bild et al,
2006). Results of different clinical trials show that positive
immunostaining for HER-2/neu or EGFR does not reliably predict
response to ErbB-targeted therapy (Ciardiello and Tortora, 2008).
A possible better marker of response to EGFR- and HER-2/neu-
targeted therapies is activation or downregulation of downstream
pathways. Indeed, positive immunostaining for pAKT, pERK,
PTEN and EGFRvIII has been reported to predict sensitivity to
EGFR tyrosine kinase inhibitors in non-small-cell lung cancer and
glioblastoma (Han et al, 2004; Mellinghoff et al, 2005).
The association of pAKT and pERK in relation to response to
ErbB-targeted therapy in ovarian cancer has not been studied yet,
but expression of these proteins might be used as a marker of
responsiveness to targeted therapies. Our results show that 8.3 and
36.9% of tumours show positive pAKT and pERK staining,
respectively, indicating that only a subgroup of patients might
benefit from agents directed against these pathways. As pERK is
overexpressed in approximately one-third of primary ovarian
tumours and 65% of tumour samples from primary chemo-
resistant tumours obtained after chemotherapy, treatment of
patients with Ras/Raf/MEK/Erk-targeted agents appears to be an
interesting therapeutic option (Messersmith et al, 2006).
In contrast to previous studies, we show a low percentage of
pAKT-positive tumours (Altomare et al, 2004; Wang et al, 2005).
The discrepancy between our results and those obtained in
previous studies is not likely to be due to methodological
variability. We have used the same well-characterised antibody
Table 3 Relationship between proteins and clinicopathological characteristics
HER2 EGFR pEGFR pAKT pERK PTEN
Variable Neg Pos P Neg Pos P Neg Pos P Neg Pos P Neg Pos P Neg Pos P
Age
o58 years 110/113 3/113 0.14 106/112 6/112 0.44 99/113 14/113 0.84 104/114 10/114 1.00 69/108 39/108 0.89 38/111 73/111 0.31
458 years 108/117 9/117 106/116 10/116 102/115 13/115 105/114 9/114 71/114 43/114 31/113 82/113
Stage
Early 59/62 3/62 1.00* 56/61 5/61 0.77* 51/60 9/60 0.49 60/91 1/61 0.029 38/59 21/59 0.88 27/60 33/60 0.006
Late 157/166 9/166 154/165 11/165 148/166 18/166 147/165 18/165 101/161 60/161 41/162 121/162
Histology
Serous 123/128 5/128 0.38 123/127 4/127 0.017 111/127 16/127 0.84 115//126 11/126 1.00 77/123 46/123 0.89 31/124 93/124 0.042
Other 95/102 7/102 89/101 12/101 90/101 11/101 94/102 8/102 63/99 36/99 38/100 62/100
Grade
I/II 84/89 5/89 1.00* 82/87 5/87 0.78 75/88 13/88 0.18 85/89 4/89 0.19 49/85 36/85 0.24 32/87 55/87 0.17
III/undiff 112/118 6/118 109/118 9/118 107/117 10/117 104/116 12/116 76/114 38/114 31/114 83/114
Res. tumour
o2cm 105/109 4/109 0.54 100/107 7/107 1.00 95/107 12/107 0.84 102/108 6/108 0.31 70/102 32/102 0.15 34/104 70/104 0.55
X 2cm 102/109 7/109 101/109 8/109 95/109 14/109 97/108 11/108 63/108 45/108 31/108 77/108
Neg¼negative; Pos¼positive; Res. tumour¼residual tumour after primary surgery; undiff¼undifferentiated. P-values are derived from the w
2-test or Fischer’s exact test, where
appropriate (*signifies the use of the Fischer’s exact test).
Table 4 Results of univariate survival analysis
Univariate Cox regression analysis
Hazard
ratio
95% confidence
interval P-value
Progression-free survival
EGFR positive 0.55 0.26–1.17 0.12
HER-2/neu positive 0.98 0.46–2.10 0.96
pEGFR positive 0.62 0.35–1.06 0.09
pAKT positive 0.88 0.46–1.67 0.69
pERK positive 1.09 0.77–1.54 0.64
PTEN negative 0.48 0.32–0.72 o0.001
Overall survival
EGFR positive 0.84 0.43–1.65 0.43
HER-2/neu positive 1.02 0.48–2.20 0.94
pEGFR positive 0.64 0.36–1.39 0.13
pAKT positive 1.05 0.58–1.91 0.86
pERK positive 1.04 0.73–1.48 0.84
PTEN negative 0.66 0.44–0.097 0.037
Bold signifies Po0.05.
Table 5 Results of multivariate survival analysis
Multivariate Cox regression analysis
Hazard
ratio
95% confidence
interval P-value
Progression-free survival
PTEN-negative tumour 0.57 0.36–0.90 0.015
Age458 years 1.09 0.74–1.60 0.671
FIGO stage III/IV 2.51 1.21–5.19 0.013
Serous tumour type 1.44 0.92–2.24 0.109
Differentiation grade III/IV 1.40 0.89–2.19 0.144
Suboptimal debulking 2.37 1.43–3.50 o0.001
Overall survival
PTEN-negative tumour 0.96 0.62–1.47 0.833
Age458 years 1.24 0.83–1.83 0.291
FIGO stage III/IV 2.56 1.14–5.74 0.023
Serous tumour type 1.46 0.93–2.76 0.100
Differentiation grade III/IV 1.50 0.94–2.38 0.090
Suboptimal debulking 2.51 1.57–4.00 o0.001
PTEN¼phosphatase and tensin homologue deleted on chromosome 10;
FIGO¼International Federation of Gynaecology and Obstetrics. Bold signifies
Po0.05.
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sthat was used in previous studies, with a comparable staining
protocol. In all our experiments, the ovarian cancer cell line A2780
served as a positive control. Expression of pAKT in this cell line
was confirmed by western blotting (data not shown). In agreement
with previous large studies, we also show a relatively low
percentage of EGFR- and HER-2/neu-overexpressing tumours
(Bookman et al, 2003; Lassus et al, 2006). We therefore conclude
that in this group of ovarian carcinomas, signalling of EGFRs via
the AKT pathway might be important only in specific subgroups of
ovarian tumours.
Surprisingly, we identified a significant relationship between
positive expression of AKT and positive expression of PTEN. The
role of PTEN as a negative regulator of AKT is well documented in
both cell line models and tumour samples (Stambolic et al, 1998;
Sun et al, 1999; Kurose et al, 2001; Choe et al, 2003). However,
others have also identified a positive correlation between
expressions of the two proteins by immunostaining (Panigrahi
et al, 2004; Slipicevic et al, 2005; Wang et al, 2005). This might
mean that in tumours, the regulatory relationship between AKT
and PTEN is not linear. In breast and ovarian cancer, it has been
shown that aberrations of the PI3K and PTEN genes are mutually
exclusive (Saal et al, 2005; Press et al, 2008), resulting in
constitutive activation of the PI3K pathway in the presence of an
intact PTEN. Loss of PTEN may also contribute to tumourigenesis
and progression via AKT-independent pathways, such as the p53
pathway (Blanco-Aparicio et al, 2007).
In contrast to available data in literature we did not detect any
EGFRvIII in this large group of ovarian carcinomas. Moscatello
et al reported that EGFRvIII is expressed in 75% of ovarian
tumours, but this high percentage could not be confirmed in
subsequent studies (Jungbluth et al, 2003; Lassus et al, 2006). We
determined EGFRvIII status by immunohistochemistry using the
well-defined antibody DH8.3 and verified our results at the RNA
level by RT–PCR on a subset of 45 tumours showing positive
immunostaining for EGFR or downstream targets. As EGFRvIII
heterodimerises with wtEGFR, is constitutively phosphorylated
and activates AKT and to a lesser extent ERK, we hypothesised that
the chance of finding EGFRvIII-positive tumours was largest in
this subgroup (Montgomery et al, 1995; Li et al, 2004; Luwor et al,
2004). As we did not detect any EGFRvIII positivity in this
subgroup, nor in 10 tumours that did not overexpress any of the
studied markers, our data strongly suggest that EGFRvIII
signalling does not play a major role in ovarian cancer.
In the current retrospective study we investigated protein
expression in a large well-defined patient population. However,
our results showed that protein expression was mainly important
in specific patient groups. Unfortunately, these subgroups were too
small to perform valid multivariate analysis. Furthermore, not all
patients received the same chemotherapeutic treatment. Future
studies should determine the prognostic value of PTEN staining,
especially in early stage patients and poorly differentiated serous
tumours, in large prospective studies including homogeneously
treated patients.
In summary, we demonstrated that negative PTEN staining is
associated with favourable patient and tumour characteristics, and
independently predicts improved PFS. The importance of pAKT
and pERK expression as downstream markers of responsiveness to
receptor tyrosine kinase-targeted therapies deserves to be eval-
uated in clinical trials. A better understanding of these pathways
and their role in ovarian cancer will enable us to use targeted drugs
more efficiently, and to identify (groups of) genes that predict
prognosis more accurately.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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